Cinctive Capital Management LP Reduces Stock Position in DaVita Inc. (NYSE:DVA)

Cinctive Capital Management LP cut its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 24.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,357 shares of the company's stock after selling 15,210 shares during the period. Cinctive Capital Management LP owned approximately 0.06% of DaVita worth $6,933,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in DVA. JPMorgan Chase & Co. boosted its stake in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Amundi boosted its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. KBC Group NV boosted its position in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock valued at $47,281,000 after buying an additional 2,636 shares during the last quarter. Nordea Investment Management AB raised its position in DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock valued at $29,430,000 after buying an additional 84,375 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DVA shares. Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, StockNews.com lowered DaVita from a "buy" rating to a "hold" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $166.33.

DaVita Stock Performance

DVA traded down $4.37 during midday trading on Friday, reaching $149.37. The company had a trading volume of 1,009,511 shares, compared to its average volume of 811,855. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The business has a 50-day moving average price of $155.75 and a two-hundred day moving average price of $157.28. The stock has a market cap of $11.95 billion, a PE ratio of 13.91, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.